E. Campo, S. Swerdlow, N. Harris, S. Pileri, H. Stein et al., The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications, Blood, vol.117, issue.19, pp.5019-5051, 2011.
DOI : 10.1182/blood-2011-01-293050

K. Smedby and H. Hjalgrim, Epidemiology and etiology of mantle cell lymphoma and other non-Hodgkin lymphoma subtypes, Seminars in Cancer Biology, vol.21, issue.5, pp.293-301, 2011.
DOI : 10.1016/j.semcancer.2011.09.010

C. Leux, M. Maynadié, X. Troussard, Q. Cabrera, A. Herry et al., Mantle cell lymphoma epidemiology: a population-based study in France, Annals of Hematology, vol.91, issue.11, pp.1327-1360, 2014.
DOI : 10.1007/s00277-014-2049-5

B. Shah, P. Martin, and E. Sotomayor, Mantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches, Cancer Control J Moffitt Cancer Cent, vol.19, pp.227-262, 2012.

C. Schöllkopf, M. Melbye, L. Munksgaard, K. Smedby, K. Rostgaard et al., Borrelia infection and risk of non-Hodgkin lymphoma, Blood, vol.111, issue.12, pp.5524-5533, 2008.
DOI : 10.1182/blood-2007-08-109611

S. Wang, S. Slager, P. Brennan, E. Holly, D. Sanjose et al., Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10 211 cases and 11 905 controls from the International Lymphoma Epidemiology Consortium (InterLymph), Blood, vol.109, issue.8, pp.3479-88, 2007.
DOI : 10.1182/blood-2006-06-031948

C. Skibola, P. Bracci, A. Nieters, A. Brooks-wilson, S. De-sanjosé et al., Tumor Necrosis Factor (TNF) and Lymphotoxin-?? (LTA) Polymorphisms and Risk of Non-Hodgkin Lymphoma in the InterLymph Consortium, American Journal of Epidemiology, vol.171, issue.3, pp.267-76, 2010.
DOI : 10.1093/aje/kwp383

M. Dreyling, W. Hiddemann, M. European, and . Network, Current treatment standards and emerging strategies in mantle cell lymphoma, Hematology, vol.2009, issue.1, pp.542-51, 2009.
DOI : 10.1182/asheducation-2009.1.542

J. Vose, Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management, American Journal of Hematology, vol.104, issue.6, pp.604-613, 2012.
DOI : 10.1002/ajh.23176

R. Chandran, S. Gardiner, M. Simon, and S. Spurgeon, Survival trends in mantle cell lymphoma in the United States over 16 years 1992???2007, Leukemia & Lymphoma, vol.14, issue.1, pp.1488-93, 2007.
DOI : 10.1002/ajh.21036

E. Hoster, M. Dreyling, W. Klapper, C. Gisselbrecht, A. Van-hoof et al., A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma, Blood, vol.111, issue.2, pp.558-65, 2008.
DOI : 10.1182/blood-2007-06-095331

M. Gerlinger, A. Rowan, S. Horswell, J. Larkin, D. Endesfelder et al., Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing, New England Journal of Medicine, vol.366, issue.10, pp.883-92, 2012.
DOI : 10.1056/NEJMoa1113205

I. Onakpoya, E. Spencer, M. Thompson, and C. Heneghan, Effectiveness, safety and costs of orphan drugs: an evidence-based review, BMJ Open, vol.5, p.7199, 2015.

M. Wang, S. Rule, P. Martin, A. Goy, R. Auer et al., Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma, New England Journal of Medicine, vol.369, issue.6, pp.507-523, 2013.
DOI : 10.1056/NEJMoa1306220

E. Campo and S. Rule, Mantle cell lymphoma: evolving management strategies, Blood, vol.125, issue.1, pp.48-55, 2015.
DOI : 10.1182/blood-2014-05-521898

A. Souers, J. Leverson, E. Boghaert, S. Ackler, N. Catron et al., ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets, Nature Medicine, vol.559, issue.2, pp.202-210, 2013.
DOI : 10.1038/leu.2009.151

C. Touzeau, C. Dousset, L. Gouill, S. Sampath, D. Leverson et al., The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma, Leukemia, vol.21, issue.1, pp.210-212, 2014.
DOI : 10.1038/leu.2013.216

D. Chiron, C. Dousset, C. Brosseau, C. Touzeau, S. Maïga et al., Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma, Oncotarget, vol.6, issue.11, pp.8750-8759, 2015.
DOI : 10.18632/oncotarget.3275

P. Allart-vorelli, B. Porro, F. Baguet, A. Michel, and F. Cousson-gélie, Haematological cancer and quality of life: a systematic literature review, Blood Cancer Journal, vol.46, issue.4, p.305, 2015.
DOI : 10.1016/S1470-2045(07)70287-5

R. Jensen, N. Arora, K. Bellizzi, J. Rowland, A. Hamilton et al., Health-related quality of life among survivors of aggressive non-Hodgkin lymphoma, Cancer, vol.112, issue.3, pp.672-80, 2013.
DOI : 10.1002/cncr.27781

S. Smith, D. Mayer, S. Zimmerman, C. Williams, H. Benecha et al., Quality of Life Among Long-Term Survivors of Non-Hodgkin Lymphoma: A Follow-Up Study, Journal of Clinical Oncology, vol.31, issue.2, pp.272-281, 2013.
DOI : 10.1200/JCO.2011.40.6249

A. Trotti, A. Colevas, A. Setser, V. Rusch, D. Jaques et al., CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment, Seminars in Radiation Oncology, vol.13, issue.3, pp.176-81, 2003.
DOI : 10.1016/S1053-4296(03)00031-6

B. Linn, M. Linn, and L. Gurel, CUMULATIVE ILLNESS RATING SCALE, Journal of the American Geriatrics Society, vol.22, issue.5, pp.622-628, 1968.
DOI : 10.1111/j.1532-5415.1968.tb02103.x

J. Ware and C. Sherbourne, The MOS 36-ltem Short-Form Health Survey (SF-36), Medical Care, vol.30, issue.6, pp.473-83, 1992.
DOI : 10.1097/00005650-199206000-00002

R. Brooks, R. Rabin, and F. Charro, The Measurement and Valuation of Health Status Using EQ-5D: A European Perspective Evidence from the EuroQol BIOMED Research Programme [Internet], 2003.

F. Hlubocky, K. Webster, J. Cashy, J. Beaumont, and D. Cella, The Development and Validation of a Measure of Health-Related Quality of Life for Non-Hodgkin???s Lymphoma: The Functional Assessment of Cancer Therapy???Lymphoma (FACT-Lym), Lymphoma, vol.13, issue.9, pp.1-9, 2013.
DOI : 10.1007/BF02310555

M. Vegliante, J. Palomero, P. Perez-galan, G. Roue, G. Castellano et al., SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma, Blood, vol.121, issue.12, pp.2175-85, 2013.
DOI : 10.1182/blood-2012-06-438937

S. Surget, D. Chiron, P. Gomez-bougie, G. Descamps, E. Ménoret et al., Cell Death via DR5, but not DR4, Is Regulated by p53 in Myeloma Cells, Cancer Research, vol.72, issue.17, pp.4562-73, 2012.
DOI : 10.1158/0008-5472.CAN-12-0487

C. Touzeau, J. Ryan, J. Guerriero, P. Moreau, T. Chonghaile et al., BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics, Leukemia, vol.120, issue.3, pp.761-765, 2016.
DOI : 10.1016/j.ymeth.2013.04.006

URL : https://hal.archives-ouvertes.fr/inserm-01411102

J. Burger and R. Ford, The microenvironment in mantle cell lymphoma: Cellular and molecular pathways and emerging targeted therapies, Seminars in Cancer Biology, vol.21, issue.5, pp.308-320, 2011.
DOI : 10.1016/j.semcancer.2011.09.006

M. Klanova, T. Soukup, R. Jaksa, J. Molinsky, L. Lateckova et al., Mouse models of mantle cell lymphoma, complex changes in gene expression and phenotype of engrafted MCL cells: implications for preclinical research, Laboratory Investigation, vol.13, issue.7, pp.806-823, 2014.
DOI : 10.1093/bioinformatics/btm311

R. Team, R: A language and environment for statistical computing [Internet] Vienna: R Foundation for Statistical Computing Available from: URL http